The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma

F. Shoji, T. Yano, I. Yoshino, D. Mori, F. Yamasaki, H. Kohno, Y. Maehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse. We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. Methods: From 2002 to 2006, gefitinib was administered to in 34 postoperative recurrent lung adenocarcinoma patients. There were 13 men and 21 women with a mean age of 65 years. Twenty patients had never smoked while 14 were former smokers. Epidermal growth factor receptor (EGFR) gene mutation was measured using surgical specimens of the primary tumor. Results: The study group showed 1 complete response, 16 partial responses, 7 stable diseases and 8 progressive diseases. Mutations of EGFR gene were detected in 20 of 34 patients. Only the presence of EGFR gene mutations was significantly associated with the clinical response of gefitinib in our limited study (p = 0.036). In 9 of 12 responders, gefitinib treatment failed due to the appearance of new lesions. Conclusions: Gefitinib was significantly effective for patients with mutations of the EGFR gene and most responders failed due to the appearance of new lesions without progression of the pre-existent target lesions.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

erbB-1 Genes
Recurrence
Mutation
Non-Small Cell Lung Carcinoma
gefitinib
Adenocarcinoma of lung
Treatment Failure
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. / Shoji, F.; Yano, T.; Yoshino, I.; Mori, D.; Yamasaki, F.; Kohno, H.; Maehara, Y.

In: European Journal of Surgical Oncology, Vol. 34, No. 1, 01.01.2008, p. 89-93.

Research output: Contribution to journalArticle

Shoji, F. ; Yano, T. ; Yoshino, I. ; Mori, D. ; Yamasaki, F. ; Kohno, H. ; Maehara, Y. / The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. In: European Journal of Surgical Oncology. 2008 ; Vol. 34, No. 1. pp. 89-93.
@article{e36b6daf1aee46f38b188a5055016d11,
title = "The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma",
abstract = "Aims: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse. We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. Methods: From 2002 to 2006, gefitinib was administered to in 34 postoperative recurrent lung adenocarcinoma patients. There were 13 men and 21 women with a mean age of 65 years. Twenty patients had never smoked while 14 were former smokers. Epidermal growth factor receptor (EGFR) gene mutation was measured using surgical specimens of the primary tumor. Results: The study group showed 1 complete response, 16 partial responses, 7 stable diseases and 8 progressive diseases. Mutations of EGFR gene were detected in 20 of 34 patients. Only the presence of EGFR gene mutations was significantly associated with the clinical response of gefitinib in our limited study (p = 0.036). In 9 of 12 responders, gefitinib treatment failed due to the appearance of new lesions. Conclusions: Gefitinib was significantly effective for patients with mutations of the EGFR gene and most responders failed due to the appearance of new lesions without progression of the pre-existent target lesions.",
author = "F. Shoji and T. Yano and I. Yoshino and D. Mori and F. Yamasaki and H. Kohno and Y. Maehara",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2007.03.005",
language = "English",
volume = "34",
pages = "89--93",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma

AU - Shoji, F.

AU - Yano, T.

AU - Yoshino, I.

AU - Mori, D.

AU - Yamasaki, F.

AU - Kohno, H.

AU - Maehara, Y.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Aims: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse. We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. Methods: From 2002 to 2006, gefitinib was administered to in 34 postoperative recurrent lung adenocarcinoma patients. There were 13 men and 21 women with a mean age of 65 years. Twenty patients had never smoked while 14 were former smokers. Epidermal growth factor receptor (EGFR) gene mutation was measured using surgical specimens of the primary tumor. Results: The study group showed 1 complete response, 16 partial responses, 7 stable diseases and 8 progressive diseases. Mutations of EGFR gene were detected in 20 of 34 patients. Only the presence of EGFR gene mutations was significantly associated with the clinical response of gefitinib in our limited study (p = 0.036). In 9 of 12 responders, gefitinib treatment failed due to the appearance of new lesions. Conclusions: Gefitinib was significantly effective for patients with mutations of the EGFR gene and most responders failed due to the appearance of new lesions without progression of the pre-existent target lesions.

AB - Aims: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse. We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. Methods: From 2002 to 2006, gefitinib was administered to in 34 postoperative recurrent lung adenocarcinoma patients. There were 13 men and 21 women with a mean age of 65 years. Twenty patients had never smoked while 14 were former smokers. Epidermal growth factor receptor (EGFR) gene mutation was measured using surgical specimens of the primary tumor. Results: The study group showed 1 complete response, 16 partial responses, 7 stable diseases and 8 progressive diseases. Mutations of EGFR gene were detected in 20 of 34 patients. Only the presence of EGFR gene mutations was significantly associated with the clinical response of gefitinib in our limited study (p = 0.036). In 9 of 12 responders, gefitinib treatment failed due to the appearance of new lesions. Conclusions: Gefitinib was significantly effective for patients with mutations of the EGFR gene and most responders failed due to the appearance of new lesions without progression of the pre-existent target lesions.

UR - http://www.scopus.com/inward/record.url?scp=37349103881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349103881&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2007.03.005

DO - 10.1016/j.ejso.2007.03.005

M3 - Article

C2 - 17449217

AN - SCOPUS:37349103881

VL - 34

SP - 89

EP - 93

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -